GSK plc / Bellus Health Inc.

Refractory Chronic Cough

Competitive Landscape

Camlipixant (BLU-5937) is a selective P2X3 antagonist in Phase 3 (CALM-1, CALM-2) for refractory/unexplained chronic cough (RCC/UCC), positioned to enter a category with no FDA-approved therapies. Competitive landscape groups by MOA class: P2X3 receptor antagonists (direct), neuromodulators (off-label anchors), opioid-class antitussives, and peripheral sensitizer blockade. In the P2X3 antagonist class, Merck's Lyfnua (gefapixant, P2X3/P2X2/3) was approved in EU/Japan/UK/Switzerland for RCC but received an FDA Complete Response Letter in 2022 (efficacy/benefit-risk concerns), leaving the US market open; real-world launch metrics in Japan (approved 2022) show dysgeusia-driven persistence challenges. Shionogi's sivopixant (Phase 3, terminated in some indications for efficacy) and Bayer's eliapixant (P2X3, development suspended 2022 after hepatotoxicity signal) are the two other class entrants, both impaired. Camlipixant's cleaner selectivity for P2X3 homotrimer (avoiding P2X2/3 heterotrimer taste pathway) is the franchise-defining differentiation. In neuromodulator off-label standard-of-care, gabapentin (generic, Pfizer Neurontin originator), pregabalin (Lyrica, Pfizer, generic), and amitriptyline anchor specialist practice despite lacking cough labels. In centrally-acting antitussives, codeine- and dextromethorphan-containing formulations remain OTC/legacy options with no RCC-specific label. Commercial takeaway: if CALM-1/CALM-2 read positive, camlipixant is the presumptive US market creator with no FDA-approved competitor; GSK inherits de facto first-mover economics.